Kokino Injection contains Iron Sucrose 100mg/5ml, an intravenous iron preparation indicated for the treatment of iron deficiency anemia, particularly in patients with chronic kidney disease (CKD) undergoing hemodialysis or those who are intolerant or unresponsive to oral iron therapy. Iron Sucrose is a complex of polynuclear iron(III)-hydroxide in sucrose, designed to deliver bioavailable iron directly to the reticuloendothelial system, facilitating effective erythropoiesis. The injection is administered intravenously, allowing rapid replenishment of iron stores and correction of anemia. Kokino Injection is contraindicated in patients with known hypersensitivity to iron sucrose or any of its components, and caution is advised in cases of iron overload or disturbances in iron metabolism. Adverse effects may include transient hypotension, nausea, headache, and injection site reactions; serious hypersensitivity reactions, though rare, require immediate medical attention. Dosage and administration should be individualized based on the patient’s iron status, hemoglobin levels, and clinical response, with regular monitoring of hematologic parameters to avoid iron overload. Kokino Injection offers a safe and effective option for iron repletion in patients unable to tolerate or absorb oral iron, improving quality of life and clinical outcomes in iron deficiency anemia management.